Skip to Main Content

Paper Details

The TBK1/IKKε inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis.
JCI Insight
1
2022
Amlexanox, Cardiovascular diseases, IKK, Ldlr-/-, TANK-binding kinase 1, TBK1, WD, amlexanox, atherosclerosis, bile, bile acid, cholesterol, diabetic, dyslipidemia, eosinophilia, glucose, human, hypercholesterolemia, hypertriglyceridemia, inflammation, insulin, mice, monocytosis, patients, vascular dysfunction
Author NameAffiliation
Christopher K GlassUniversity of California, San Diego (university of california san diego)
Christopher K Glass
Christopher K GlassUniversity of California, San Diego (university of california san diego)
Christopher K Glass
Joseph L WitztumUniversity of California, San Diego (university of california san diego)
  • 1 - 5

Datasets

Release 1.2